- Made Scientific has partnered with Syenex to enhance the scalability and efficiency of engineered T cell therapies using Syenex’s UltraCell™ and RapidCell™ bioengineering systems.
- Initial proof-of-concept studies show up to a tenfold improvement in gene delivery efficiency and the potential to reduce manufacturing timelines and costs.
Made Scientific, a cell therapy CDMO, and Syenex, a synthetic biology company, have announced a technology partnership aimed at improving engineered T cell therapy manufacturing. The collaboration will use Syenex’s UltraCell™ and RapidCell™ platforms to enhance gene delivery efficiency and streamline production workflows.
The partnership builds on early proof-of-concept studies, demonstrating that the RapidCell™ system can serve as an alternative to standard transduction and activation reagents. Data indicate it is highly specific, may enable transduction and activation of non-enriched cell populations, and offers more cost-effective and efficient workflows.
The collaboration aims to address scalability, cost, and time challenges associated with traditional lentiviral- and retroviral-vector-engineered T cell therapy manufacturing. Made Scientific and Syenex intend to launch a customer-accessible manufacturing platform process incorporating the technology in 2026.
“By incorporating Syenex’s advanced systems into Made Scientific’s manufacturing processes, we’re enabling access to an efficient and cost-effective platform that can be leveraged by therapeutic developers to accelerate the path from R&D to GMP, making life-saving therapies more accessible for patients in need.”
Syed T. Husain, Chairman & CEO of Made Scientific
The companies plan to continue developing next-generation T cell therapies, combining contract manufacturing capabilities with advanced bioengineering systems to reduce costs and timelines for cell therapy developers.
